Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
3.040
+0.190 (6.67%)
At close: Aug 13, 2025, 4:00 PM
3.060
+0.020 (0.66%)
Pre-market: Aug 14, 2025, 5:49 AM EDT
Achilles Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Achilles Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $10, which forecasts a 228.95% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $14.
Price Target: $10 (+228.95%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 2, 2025.
Analyst Ratings
The average analyst rating for Achilles Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +360.53% | Apr 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +360.53% | Feb 20, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $35 → $6 | Strong Buy | Maintains | $35 → $6 | +97.37% | Feb 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +360.53% | Feb 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $140 | Strong Buy | Reiterates | $140 | +4,505.26% | Nov 1, 2024 |
Financial Forecast
Revenue This Year
n/a
from 3.34M
Revenue Next Year
6.80M
EPS This Year
-2.23
from -9.85
EPS Next Year
-1.86
from -2.23
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 14.0M | 28.0M | ||
| Avg | n/a | 6.8M | 27.2M | ||
| Low | n/a | n/a | 26.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 311.8% | ||
| Avg | - | - | 300.0% | ||
| Low | - | - | 284.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.10 | -1.05 | 0.05 | ||
| Avg | -2.23 | -1.86 | 0.05 | ||
| Low | -2.32 | -2.60 | 0.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.